McCarthy Sean A. Form 4 March 05, 2018

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF

SECURITIES

OMB APPROVAL OMB

Number:

3235-0287

Expires:

January 31, 2005

0.5

Estimated average

response...

burden hours per

if no longer subject to Section 16. Form 4 or Form 5 obligations may continue.

See Instruction

Check this box

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section

30(h) of the Investment Company Act of 1940

1(b).

(Print or Type Responses)

1. Name and Address of Reporting Person * McCarthy Sean A.

2. Issuer Name and Ticker or Trading Symbol

CytomX Therapeutics, Inc. [CTMX]

5. Relationship of Reporting Person(s) to

Issuer

below)

(Last) (First)

(Middle)

3. Date of Earliest Transaction

(Check all applicable)

(Month/Day/Year)

X Director 10% Owner X_ Officer (give title Other (specify

President and CEO

C/O CYTOMX THERAPEUTICS. INC., 151 OYSTER POINT BLVD, SUITE 400

(Street)

4. If Amendment, Date Original

6. Individual or Joint/Group Filing(Check

Applicable Line)

Filed(Month/Day/Year)

03/01/2018

X Form filed by One Reporting Person Form filed by More than One Reporting

SOUTH SAN FRANCISCO, CA 94080

(City)	(State)	(Zip) Tab	le I - Non-	Derivative	Secur	ities Acqui	red, Disposed of,	or Beneficial	ly Owned
1.Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)	4. Securit for Dispos (Instr. 3, 4	ed of	` ′	5. Amount of Securities Beneficially Owned Following Reported Transaction(s)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	03/01/2018		Code V	Amount 10,516	or (D) A	Price \$ 1.5749	(Instr. 3 and 4) 15,159	D	
Common Stock	03/01/2018		M	9,000	A	\$ 1.1339	24,159	D	
Common Stock	03/01/2018		M	62	A	\$ 0.945	24,221	D	
Common Stock	03/01/2018		S <u>(1)</u>	19,578	D	\$ 29.428 (2)	4,643	D	

Common			See
	154,237	I	footnote
Stock	- , - :		(3)
			<u>``</u>

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of SEC 1474 information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

(9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transactic Code (Instr. 8)	ransactionDerivative ode Securities		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Underlying Securities (Instr. 3 and 4)	
				Code V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	\$ 1.5749	03/01/2018		M		10,516	<u>(4)</u>	02/08/2025	Common Stock	10,516
Stock Option (Right to Buy)	\$ 1.1339	03/01/2018		M		9,000	<u>(5)</u>	09/20/2021	Common Stock	9,000
Stock Option (Right to Buy)	\$ 0.945	03/01/2018		M		62	<u>(5)</u>	02/25/2023	Common Stock	62

Reporting Owners

Reporting Owner Name / Address	Relationships						
FG	Director	10% Owner	Officer	Other			
McCarthy Sean A.							
C/O CYTOMX THERAPEUTICS, INC.	X		Dragidant and CEO				
151 OYSTER POINT BLVD, SUITE 400	X President and CE		President and CEO				
SOUTH SAN FRANCISCO, CA 94080							

Reporting Owners 2

Signatures

/s/ Debanjan Ray, as Attorney-in-Fact for Sean A. McCarthy

03/05/2018

**Signature of Reporting Person

Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) The sale was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan.
 - The price reported in Column 4 is a weighted average sale price. These shares were sold in multiple transactions at prices ranging from
- (2) \$29.00 to \$29.90, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
- (3) Held in McCarthy Family Trust dated August 9, 2001, Sean A. McCarthy and Jeanette J. McCarthy, Trustees.
- (4) This option vests in 48 substantially equal monthly installments starting on the last day of January 2015.
- (5) 100% of the shares subject to the option are fully vested and exercisable.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

Signatures 3